Pharmacological management of polycystic kidney disease

Bibliography

• Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-85
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301
   PubMed Web of Science ®Google Scholar
• Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321-37
   PubMed Web of Science ®Google Scholar
• Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012;7:479-86
   PubMed Web of Science ®Google Scholar
• Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999;353:103-7
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013;24:1006-13
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009;76:149-68
   PubMed Web of Science ®Google Scholar
• Lentine KL, Xiao H, Machnicki G, et al. Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:1471-9
   PubMed Web of Science ®Google Scholar
• Helal I, Reed B, Mettler P, et al. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 2012;36:362-70
   PubMed Web of Science ®Google Scholar
• Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009;5:221-8
   PubMed Web of Science ®Google Scholar
• Xu HW, Yu SQ, Mei CL, et al. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011;42:204-6
   PubMed Web of Science ®Google Scholar
• Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010;17:173-80
   PubMed Web of Science ®Google Scholar
• Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006;354:2122-30
   PubMed Web of Science ®Google Scholar
• Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009;75:235-41
   PubMed Web of Science ®Google Scholar
• Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010;6:96-106
   Google Scholar
• Antiga L, Piccinelli M, Fasolini G, et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 2006;1:754-60
   Google Scholar
• Caroli A, Antiga L, Conti S, et al. Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. Am J Pathol 2011;179:619-27
   Google Scholar
• Torres VE, King BF, Chapman AB, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007;2:112-20
   Google Scholar
• Bae KT, Tao C, Zhu F, et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 2009;4:719-25
   Google Scholar
• Torres VE. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis 2010;17:190-204
   Google Scholar
• Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens 2012;21:189-94
   Google Scholar
• Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50
   PubMed Web of Science ®Google Scholar
• Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003;63:678-85
   PubMed Web of Science ®Google Scholar
• Torres VE, Grantham JJ, Chapman AB, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:640-7
   Google Scholar
• Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006;2:40-55; quiz 55
   PubMedGoogle Scholar
• Chang MY, Ong AC. New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol 2013;76:524-35
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol 2013;17:317-26
   Google Scholar
• Chang MY, Ong AC. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol 2008;108:p1-7
   Web of Science ®Google Scholar
• Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 2012;120:c25-34; discussion c35
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014;25:18-32
   PubMed Web of Science ®Google Scholar
• Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29
   Google Scholar
• Wu M, Arcaro A, Varga Z, et al. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 2009;297:23
   Google Scholar
• Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007;30:253-9
   PubMed Web of Science ®Google Scholar
• Zafar I, Ravichandran K, Belibi FA, et al. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 2010;78:754-61
   PubMed Web of Science ®Google Scholar
• Zafar I, Belibi FA, He Z, et al. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009;24:2349-53
   PubMed Web of Science ®Google Scholar
• Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006;103:5466-71
   PubMed Web of Science ®Google Scholar
• Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006;21:598-604
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Grandaliano G, et al. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant 2012;27:3560-7
   PubMed Web of Science ®Google Scholar
• Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:820-9
   PubMed Web of Science ®Google Scholar
• Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:830-40
   PubMed Web of Science ®Google Scholar
• Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010;21:1031-40
   PubMed Web of Science ®Google Scholar
• He Q, Lin C, Ji S, et al. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials. Am J Med Sci 2012;344:491-7
   Web of Science ®Google Scholar
• Canaud G, Knebelmann B, Harris PC, et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant 2010;10:1701-6
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-16
   PubMed Web of Science ®Google Scholar
• Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010;5:783-9
   PubMed Web of Science ®Google Scholar
• van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;137:1661-8. e1661-1662
   PubMed Web of Science ®Google Scholar
• Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-61
   PubMed Web of Science ®Google Scholar
• Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012;35:266-74
   PubMed Web of Science ®Google Scholar
• Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012;27:3532-9
   PubMed Web of Science ®Google Scholar
• Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013;382:1485-95
   PubMed Web of Science ®Google Scholar
• Meijer E, Drenth JP, d’Agnolo H, et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2014;63:446-55
   PubMedGoogle Scholar
• Gattone VH II, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-6
   PubMed Web of Science ®Google Scholar
• Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10:363-4
   PubMed Web of Science ®Google Scholar
• Wang X, Gattone V II, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846-51
   PubMed Web of Science ®Google Scholar
• Meijer E, Gansevoort RT, de Jong PE, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 2011;26:2445-53
   Google Scholar
• Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(-) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011;301:F1005-13
   PubMed Web of Science ®Google Scholar
• Meijer E, Boertien WE, Zietse R, et al. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2011;34:235-44
   Google Scholar
• Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol 2011;6:2499-507
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80:295-301
   Google Scholar
• Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 2013;84:1278-86
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18
   PubMed Web of Science ®Google Scholar
• Wuthrich RP, Mei C. Aquaretic treatment in polycystic kidney disease. N Engl J Med 2012;367:2440-2
   Google Scholar
• Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013;159:382-9
   PubMed Web of Science ®Google Scholar
• Rassi FE, Khoury HJ. Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia. Pharmgenomics Pers Med 2013;6:57-62
   Google Scholar
• Stansfield L, Hughes TE, Walsh-Chocolaad TL. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia. Ann Pharmacother 2013;47:1703-11
   PubMed Web of Science ®Google Scholar
• Campone M, Bondarenko I, Brincat S, et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012;23:610-17
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr, von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008;19:1331-41
   PubMed Web of Science ®Google Scholar
• Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol 2011;301:C522-9
   PubMed Web of Science ®Google Scholar
• Zhong Y, Deng Y, Chen Y, et al. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int 2013;84:1108-18
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104:4389-94
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008;19:1659-62
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Bencivenga N, Chahboune H, et al. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant 2010;25:2187-94
   PubMed Web of Science ®Google Scholar
• Chen D, Ma Y, Wang X, et al. Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial. Am J Kidney Dis 2014; In press
   Google Scholar
• Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991;11:653-60
   PubMed Web of Science ®Google Scholar
• Chapman AB, Johnson AM, Rainguet S, et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-7
   PubMed Web of Science ®Google Scholar
• Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12:194-200
   PubMed Web of Science ®Google Scholar
• Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-6
   PubMed Web of Science ®Google Scholar
• Gattone VH II, Siqueira TM Jr, Powell CR, et al. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med (Maywood) 2008;233:952-7
   Web of Science ®Google Scholar
• Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33
   PubMed Web of Science ®Google Scholar
• Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009;20:1888-93
   Web of Science ®Google Scholar
• Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5:102-9
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Perrone RD, et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012;81:577-85
   PubMed Web of Science ®Google Scholar
• Shetty SV, Roberts TJ, Schlaich MP. Percutaneous transluminal renal denervation: a potential treatment option for polycystic kidney disease-related pain? Int J Cardiol 2013;162:e58-9
   Google Scholar
• Prejbisz A, Kadziela J, Lewandowski J, et al. Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease. Clin Res Cardiol 2014;103:251-3
   Google Scholar
• Chen D, Ma Y, Wang X, et al. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One 2014;9(3):e92232
   Google Scholar